130 related articles for article (PubMed ID: 12163580)
1. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.
Kakimi K; Isogawa M; Chung J; Sette A; Chisari FV
J Virol; 2002 Sep; 76(17):8609-20. PubMed ID: 12163580
[TBL] [Abstract][Full Text] [Related]
2. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.
Depla E; Van der Aa A; Livingston BD; Crimi C; Allosery K; De Brabandere V; Krakover J; Murthy S; Huang M; Power S; Babé L; Dahlberg C; McKinney D; Sette A; Southwood S; Philip R; Newman MJ; Meheus L
J Virol; 2008 Jan; 82(1):435-50. PubMed ID: 17942551
[TBL] [Abstract][Full Text] [Related]
3. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen.
Isogawa M; Kakimi K; Kamamoto H; Protzer U; Chisari FV
Virology; 2005 Mar; 333(2):293-300. PubMed ID: 15721363
[TBL] [Abstract][Full Text] [Related]
4. Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation.
Tang J; Zhang J; Zhang G; Peng W; Ling N; Zhou Y; Xu H; Ren H; Chen M
mBio; 2024 Apr; 15(4):e0306823. PubMed ID: 38440978
[TBL] [Abstract][Full Text] [Related]
5. HIV-HBV Coinfection-Current Challenges for Virologic Monitoring.
Ruta S; Grecu L; Iacob D; Cernescu C; Sultana C
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238976
[TBL] [Abstract][Full Text] [Related]
6. Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B.
Fu YL; Zhou SN; Hu W; Li J; Zhou MJ; Li XY; Wang YY; Zhang P; Chen SY; Fan X; Song JW; Jiao YM; Xu R; Zhang JY; Zhen C; Zhou CB; Yuan JH; Shi M; Wang FS; Zhang C
Hepatol Int; 2023 Oct; 17(5):1125-1138. PubMed ID: 36976426
[TBL] [Abstract][Full Text] [Related]
7. Abnormally primed CD8 T cells: The Achilles' heel of CHB.
Chen X; Liu X; Jiang Y; Xia N; Liu C; Luo W
Front Immunol; 2023; 14():1106700. PubMed ID: 36936922
[TBL] [Abstract][Full Text] [Related]
8. Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B.
Huang Y; Zheng S; Guo Z; de Mollerat du Jeu X; Liang XJ; Yang Z; Zhang HY; Gao S; Liang Z
Signal Transduct Target Ther; 2022 Feb; 7(1):38. PubMed ID: 35145057
[TBL] [Abstract][Full Text] [Related]
9. Immunobiology and pathogenesis of hepatitis B virus infection.
Iannacone M; Guidotti LG
Nat Rev Immunol; 2022 Jan; 22(1):19-32. PubMed ID: 34002067
[TBL] [Abstract][Full Text] [Related]
10. Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures.
Jansen DT; Dou Y; de Wilde JW; Woltman AM; Buschow SI
Clin Transl Immunology; 2021; 10(1):e1232. PubMed ID: 33489122
[TBL] [Abstract][Full Text] [Related]
11. MHC-E-Restricted CD8
Burwitz BJ; Hashiguchi PK; Mansouri M; Meyer C; Gilbride RM; Biswas S; Womack JL; Reed JS; Wu HL; Axthelm MK; Hansen SG; Picker LJ; Früh K; Sacha JB
J Immunol; 2020 Apr; 204(8):2169-2176. PubMed ID: 32161099
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.
de Beijer MTA; Jansen DTSL; Dou Y; van Esch WJE; Mok JY; Maas MJP; Brasser G; de Man RA; Woltman AM; Buschow SI
J Virol; 2020 Mar; 94(7):. PubMed ID: 31852786
[TBL] [Abstract][Full Text] [Related]
13. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.
Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR
Hum Vaccin Immunother; 2020; 16(2):251-268. PubMed ID: 31809638
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of HBV-Specific CD8
Heim K; Neumann-Haefelin C; Thimme R; Hofmann M
Front Immunol; 2019; 10():2240. PubMed ID: 31620140
[TBL] [Abstract][Full Text] [Related]
15. HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.
Shata MTM; Abdel-Hameed EA; Rouster SD; Yu L; Liang M; Song E; Esser MT; Shire N; Sherman KE
Pathog Immun; 2019; 4(1):39-65. PubMed ID: 30815625
[TBL] [Abstract][Full Text] [Related]
16. Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection.
Li MH; Zhang L; Zhang D; Cao WH; Qi TL; Hao HX; Wang XY; Ran CP; Qu XJ; Liu SA; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Hua WH; Wan G; Cheng J; Xie Y
Chin Med J (Engl); 2018 Jan; 131(1):43-49. PubMed ID: 29271379
[TBL] [Abstract][Full Text] [Related]
17. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocytes and CD4 epitope mutations in the pre-core/core region of hepatitis B virus in chronic hepatitis B carriers in Northeast Iran.
Zhand S; Tabarraei A; Nazari A; Moradi A
Indian J Gastroenterol; 2017 Jul; 36(4):253-257. PubMed ID: 28741237
[TBL] [Abstract][Full Text] [Related]
19. Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.
Zhou C; Li C; Gong GZ; Wang S; Zhang JM; Xu DZ; Guo LM; Ren H; Xu M; Xie Q; Pan C; Xu J; Hu Z; Geng S; Zhou X; Wang X; Zhou X; Mi H; Zhao G; Yu W; Wen YM; Huang L; Wang XY; Wang B
Hum Vaccin Immunother; 2017 Sep; 13(9):1989-1996. PubMed ID: 28665747
[TBL] [Abstract][Full Text] [Related]
20. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
Bian Y; Zhang Z; Sun Z; Zhao J; Zhu D; Wang Y; Fu S; Guo J; Liu L; Su L; Wang FS; Fu YX; Peng H
Hepatology; 2017 Oct; 66(4):1067-1082. PubMed ID: 28445927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
